Genitourinary Cancers

Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.

Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.

Gopa Iyer, MD, discusses treatment-related adverse events (TRAEs) with erdafitinib (Balversa) in urothelial cancer.

John P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.

John P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.

Toni K. Choueiri, MD, discusses the findings from the phase 1/2 trial, the clinical implications of targeting HIF-2α in kidney cancer, and the potential utility of MK-6482 in clear cell RCC.

Toni K. Choueiri, MD, discusses the findings from the phase 1/2 trial, the clinical implications of targeting HIF-2α in kidney cancer, and the potential utility of MK-6482 in clear cell RCC. 

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

Thomas Powles, MD, MBBS, MRCP, director, Barts Cancer Institute, discusses the 42-month follow-up data from the phase 3 CheckMate-214 trial in advanced renal cell carcinoma (RCC).

Daniel P. Petrylak, MD, professor of medicine and urology, co-leader, Cancer Signaling Networks, Yale Cancer Center, and 2017 Giant of Cancer Care® in Genitourinary Cancers, discusses the results of the phase 1b/2 EV-103 trial in bladder cancer.

Nizar M. Tannir, MD, FACP, discusses the 42-month follow-up results from the CheckMate-214 trial in advanced renal cell carcinoma and provides perspective on other approved combinations in the frontline setting.

Although fewer patients are undergoing cytoreductive nephrectomy as systemic treatments for renal cell carcinoma improve, the modality still has a vital role to play in the treatment paradigm—even in the modern age of immune checkpoint inhibitors.

Petros Grivas, MD, PhD, discusses the future of molecular subtyping in urothelial cancer.

Although the standard of care for muscle-invasive bladder cancer is well established, not enough patients are being treated with curative intent.

Nivolumab combined with cabozantinib improved overall survival and progression-free survival compared with sunitinib in patients with previously untreated advanced renal cell carcinoma.

Guru P. Sonpavde, MD sheds light on how the COVID-19 pandemic has impacted treatment decisions for patients with bladder cancer, perioperative surgical concerns for patients at risk of COVID-19, and the preventative measures Dana-Farber Cancer Institute has put into place to reduce the risk of patients and providers contracting the virus.

The FDA has approved mitomycin gel (Jelmyto) as the first therapy to treat low-grade upper tract urothelial cancer.

Monika Joshi, MD, discusses the rationale for using durvalumab in combination with radiation therapy in patients with localized urothelial carcinoma.